Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity

Fig. 2

Short-term blinatumomab exposure enhances NK cell ADCC and viability. PBMCs depleted of T cells were cocultured with Raji cells and RTX for 7 days. Serial dilutions (from 0.75 to 50% of PBMCs) of autologous T cells were added back. A Blinatumomab (1 ng/mL) was supplemented for the first 4 h (4 h), 2 days (d1-2), 7 days (d1-7) or not added (0 h). After the indicated time, blinatumomab was washed out and the coculture was refreshed with RTX-containing medium. B, C 2-day blinatumomab enhances RTX-mediated NK cell killing of CD19+ target cells and viability. 4-h blinatumomab enhances NK cell ADCC at 12% T cells but fails to increase NK cell viability. n = 6. Student’s t test was used to calculate statistical significance. *p < 0.05; **p < 0.01; ***p < 0.001 are the comparisons between RTX + blina d1-7 versus RTX + blina 0 h; #p < 0.05, ##p < 0.01 indicate RTX + blina d1-2 versus RTX + blina 0 h; × p < 0.05 indicates RTX + blina 4 h versus RTX + blina 0 h. D PBMCs depleted of T cells were cocultured with Raji cells and RTX for 7 days. Recombinant IL-2 (20 ng/mL) was supplemented for 4 h (4 h), 2 days (d1-2), 7 days (d1-7) or not added (0 h). IL-2 was washed out and replaced by RTX-containing medium after the indicated time. E, F 2-day or 4-h IL-2 exposure enhances NK cell ADCC of CD19+ target cells. Short-term IL-2 treatment also increases the number of viable NK cells, although not statistically significant. n = 5. One-way ANOVA was used to calculate statistical significance. *p < 0.05; **p < 0.01; ***p < 0.001

Back to article page